Sette, G <br/><br/>
Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.  [electronic resource] 

 -  Cell death & disease  Aug 2015 
 - e1850 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2041-4889 
<br/><br/><label>Standard No.: </label>10.1038/cddis.2015.217  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Aged<br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Biomarkers, Pharmacological--metabolism<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Carcinoma, Squamous Cell--drug therapy<br/>Cell Line, Tumor<br/>Drug Evaluation, Preclinical<br/>ErbB Receptors--genetics<br/>Erlotinib Hydrochloride--pharmacology<br/>Female<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Mice<br/>Mice, SCID<br/>Middle Aged<br/>Neoplasm Staging<br/>Neoplastic Stem Cells--drug effects<br/>Phosphorylation--drug effects<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins p21(ras)--genetics<br/>Receptor, ErbB-2--genetics<br/>Signal Transduction<br/>Tyrosine--metabolism<br/>Xenograft Model Antitumor Assays